



COPY OF PAPERS
ORIGINALLY FILED

4700

0700

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/071,032
	Filing Date	February 8, 2002
	First Named Inventor	Richard Dennis Dyer, et al
	Group Art Unit	Unknown
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	A0000425-01-CFP

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	Copy of Information Disclosure Statement (PTO 1449) Filed 05/29/02 With Missing Art Attached Certificate of Mailing Return Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Claude F. Purchase, Jr.
Signature	<i>Claude F. Purchase, Jr.</i>
Date	6/7/02

RECEIVED

AUG 01 2002

OFFICE OF PETITIONS

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 6/7/02			
Typed or printed name	Nancy Dernbach		
Signature	<i>Nancy Dernbach</i>	Date	6/7/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Trademark, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
		DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)"	
		DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis"	
		DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto-immune diseases, etc."	
		DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
		KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
		KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
		KAUL, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim.-Forsch./Drug Res., 1982; 32(1)(6); pp 610-612	
		BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	

RECEIVED

AUG 01 2002

OFFICE OF PETITIONS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		PECORARI, Piergiorgio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
		DE MELO, S. J., et al, "5-flouro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n 1, pp 39-51	
		Chem. Abstr. 1992; 117; pp 143023e - COPY TO FOLLOW	
		FASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - COPY TO FOLLOW	
		Chem. Abstr. 1988; 109; pp 162901r - COPY TO FOLLOW	
		TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany); 1998; pp 201-206	
		RECEIVED	
		AUG 0 1 2002	
		OFFICE OF PETITIONS	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**